Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lynwood, California Clinical Trials

A listing of Lynwood, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (61) clinical trials

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

AB122 every 3 weeks (Q3W) will be evaluated in molecularly defined patient populations as described by the StrataNGS test (to be performed outside of this study protocol). Participants with any advanced tumor type will be stratified evenly by tumor biomarker status as follows: TMB-H or Strata Immune Signature positive. Each ...

Phase

5.73 miles

Learn More »

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE) Cutaneous Lupus Erythematosus (CLE) Sjogren's Syndrome Systemic Sclerosis Polymyositis and Dermatomyositis

This study will have 3 periods: screening, treatment period, and extended follow-up. The screening period is 28 days. A total of 32 participants will be enrolled in 3 cohorts with 8 participants in Cohort 1, and 12 participants each in Cohorts 2 and 3. In Cohort 1, participants will be ...

Phase

7.24 miles

Learn More »

ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Phase

8.1 miles

Learn More »

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

PRIMARY OBJECTIVES: I. Determine the dose limiting toxicity (DLT) and recommended phase II dose (RP2D) of the combination of cabozantinib s-malate (cabozantinib) and nivolumab (cabo-nivo) and separately the combination of cabozantinib, nivolumab and ipilimumab (cabo-nivo-ipi) in patients with genitourinary tumors. (Phase I) II. Assess safety and tolerability of cabozantinib, nivolumab ...

Phase

8.18 miles

Learn More »

VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVE: I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970) in combination with irinotecan hydrochloride (irinotecan) in patients with advanced solid tumors. SECONDARY OBJECTIVES: I. To estimate the safety and tolerability of VX-970 in combination with irinotecan. II. ...

Phase

8.18 miles

Learn More »

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer Prostate Cancer or Kidney Cancer

PRIMARY OBJECTIVES: I. To determine the feasibility of, and adverse events associated with, treatment with soluble ephrin type-B receptor 4 (sEphB4)-human serum albumin (HSA) (recombinant EphB4-HSA fusion protein) prior to minimally invasive robotic surgery in patients with either muscle-invasive transitional cell carcinoma of the bladder; clear cell renal cell carcinoma ...

Phase

8.18 miles

Learn More »

A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation) and to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination with ipilimumab ...

Phase

8.18 miles

Learn More »

A Study in Subjects With Advanced Solid Tumors

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This monotherapy study will also determine the RP2D of the monotherapy. This Phase 1 study will be ...

Phase

8.18 miles

Learn More »

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

This is a Phase 1, open-label, single ascending dose study of MT-3921 in subjects with spinal cord injury.

Phase

8.18 miles

Learn More »

Open-label Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

United Therapeutics Corporation (UTC) is developing a combination drug-device product which is comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and tolerability study, patients with PAH on a stable dose of Tyvaso (6 to 12 ...

Phase

8.18 miles

Learn More »